{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:28:10Z","timestamp":1772224090311,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jaad.2018.04.046","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T12:36:35Z","timestamp":1525437395000},"page":"545-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy"],"prefix":"10.1016","volume":"79","author":[{"given":"Alexandra K.","family":"Rzepecki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth N.","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.04.046_bib1","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CLC.2006.s.008","article-title":"Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer","volume":"8","author":"Perez-Soler","year":"2006","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","article-title":"Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib","volume":"15","author":"Vincenzi","year":"2010","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jaad.2018.04.046_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ejca.2015.01.008","article-title":"Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients","volume":"51","author":"Sehouli","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2018.04.046_bib4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3892\/ol.2013.1178","article-title":"Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy","volume":"5","author":"Shimizu","year":"2013","journal-title":"Oncol Lett"},{"issue":"15S","key":"10.1016\/j.jaad.2018.04.046_bib5","doi-asserted-by":"crossref","first-page":"e16122","DOI":"10.1200\/jco.2009.27.15_suppl.e16122","article-title":"Impact of nail toxicity on survival of patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel","volume":"27","author":"Scotte","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.046_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.ftd.0000158867.66994.91","article-title":"Association between\u00a0alopecia and response to chemotherapy in patients with Hodgkin lymphoma","volume":"27","author":"Elis","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jaad.2018.04.046_bib7","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.046_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2018.04.046_bib10","unstructured":"US Food and Drug Administration. Tarceva (erlotinib) label. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021743s14s16lbl.pdf. Accessed October 24, 2017."},{"issue":"4","key":"10.1016\/j.jaad.2018.04.046_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.046_bib12","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.ijrobp.2016.03.011","article-title":"Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: the XXXX experience","volume":"95","author":"Bar-Ad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.046_bib14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib15","first-page":"28","article-title":"Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer","volume":"12","author":"Dobi","year":"2013","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2018.04.046_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ad.2015.01.006","article-title":"Predictors of tumor response to cetuximab and panitumumab in 116 patients and a review of approaches to managing skin toxicity","volume":"106","author":"Jaka","year":"2015","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib17","first-page":"102","article-title":"A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer","volume":"9","author":"Boccia","year":"2010","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jaad.2018.04.046_bib18","unstructured":"US Food and Drug Administration. Iressa (gefitinib). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206995s000lbl.pdf. Accessed October 24, 2017."},{"issue":"11 Suppl 12","key":"10.1016\/j.jaad.2018.04.046_bib19","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"17","author":"P\u00e9rez-Soler","year":"2003","journal-title":"Oncology (Williston Park)"},{"issue":"16","key":"10.1016\/j.jaad.2018.04.046_bib20","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"P\u00e9rez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.04.046_bib21","first-page":"943","article-title":"A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review","volume":"8","author":"Jin","year":"2015","journal-title":"Oncotargets Ther"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.12.001","article-title":"Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)","volume":"83","author":"Tiseo","year":"2014","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4149\/neo_2013_004","article-title":"Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice","volume":"60","author":"Fiala","year":"2013","journal-title":"Neoplasma"},{"issue":"3-4","key":"10.1016\/j.jaad.2018.04.046_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000315731","article-title":"Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line","volume":"78","author":"Faehling","year":"2010","journal-title":"Oncology"},{"issue":"13","key":"10.1016\/j.jaad.2018.04.046_bib25","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejca.2013.10.006","article-title":"Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group study (E3503)","volume":"50","author":"Brahmer","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib27","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1634\/theoncologist.2011-0253","article-title":"Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101","volume":"17","author":"Chiorean","year":"2012","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.046_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/15569527.2013.780179","article-title":"Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?","volume":"32","author":"Brandi","year":"2013","journal-title":"Cutan Ocul Toxicol"},{"issue":"12","key":"10.1016\/j.jaad.2018.04.046_bib29","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1200\/JCO.2005.04.9890","article-title":"Gefitinib therapy in\u00a0advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126","volume":"24","author":"West","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.046_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.lungcan.2009.04.021","article-title":"Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers","volume":"67","author":"Tiseo","year":"2010","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.046_bib31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdi157","article-title":"Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer","volume":"16","author":"Mohamed","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2018.04.046_bib32","unstructured":"US Food and Drug Administration. Sutent (sunitinib). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021938s13s17s18lbl.pdf. Accessed October 24, 2017."},{"issue":"12","key":"10.1016\/j.jaad.2018.04.046_bib33","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jaad.2018.04.046_bib34","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients","volume":"113","author":"Donskov","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2018.04.046_bib35","unstructured":"US Food and Drug Administration. Tykerb (lapatinib). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022059s3s6lbl.pdf. Accessed October 24, 2017."},{"issue":"8","key":"10.1016\/j.jaad.2018.04.046_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw037","article-title":"Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial","volume":"108","author":"Sonnenblick","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.jaad.2018.04.046_bib37","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-09-0465","article-title":"A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas","volume":"15","author":"Bekaii-Saab","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10549-014-3148-7","article-title":"Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer","volume":"148","author":"Araki","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2018.04.046_bib39","unstructured":"US Food and Drug Administration. Afinitor (everolimus). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022334s6lbl.pdf. Accessed October 24, 2017."},{"issue":"5","key":"10.1016\/j.jaad.2018.04.046_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clgc.2016.02.012","article-title":"Correlation of stomatitis and cutaneous toxicity with clinical outcome in patients with metastatic renal-cell carcinoma treated with everolimus","volume":"14","author":"Conteduca","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jaad.2018.04.046_bib41","unstructured":"US Food and Drug Administration. Vectibix (panitumumab). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125147s080lbl.pdf. Accessed October 24, 2017."},{"issue":"suppl 18","key":"10.1016\/j.jaad.2018.04.046_bib42","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/jco.2007.25.18_suppl.4038","article-title":"Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab) [abstract]","volume":"25","author":"Humblet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.04.046_bib43","unstructured":"US Food and Drug Administration. Nexavar (sorafenib). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021923s008s009lbl.pdf. Accessed October 24, 2017."},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474124.2017.1373018","article-title":"Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis","volume":"12","author":"Wang","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/17474124.2017.1264874","article-title":"Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival","volume":"11","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.04.046_bib46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/jjco\/hyt110","article-title":"Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"43","author":"Nakano","year":"2013","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.jaad.2018.04.046_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000481241","article-title":"Hand-Foot Syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study","volume":"93","author":"Ogawa","year":"2017","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.jaad.2018.04.046_bib48","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/liv.12168","article-title":"Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma","volume":"33","author":"Cho","year":"2013","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.046_bib49","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12094-016-1537-6","article-title":"Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib","volume":"19","author":"Lamarca","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2018.04.046_bib50","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1872-034X.2012.00991.x","article-title":"Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib","volume":"42","author":"Otsuka","year":"2012","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jaad.2018.04.046_bib51","unstructured":"US Food and Drug Administration. Keytruda (pembrolizumab). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125514s014lbl.pdf. Accessed October 24, 2017."},{"issue":"9","key":"10.1016\/j.jaad.2018.04.046_bib52","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00262-017-1989-8","article-title":"The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series","volume":"66","author":"Wen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.jaad.2018.04.046_bib53","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.04.046_bib54","unstructured":"US Food and Drug Administration. Opdivo (nivolumab) injection, for intravenous use. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125554s041lbl.pdf. Accessed October 24, 2017."},{"issue":"11","key":"10.1016\/j.jaad.2018.04.046_bib55","doi-asserted-by":"crossref","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer","volume":"5","author":"Hasan Ali","year":"2016","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.04.046_bib57","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/cas.13241","article-title":"Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.jaad.2018.04.046_bib58","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2017.2106","article-title":"Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer","volume":"153","author":"Rivera","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.04.046_bib59","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.04.046_bib60","unstructured":"US Food and Drug Administration. Yervoy (ipilimumab). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s073lbl.pdf. Accessed October 24, 2017."},{"issue":"15_suppl","key":"10.1016\/j.jaad.2018.04.046_bib61","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1200\/jco.2010.28.15_suppl.8571","article-title":"Hair depigmentation as an indicator of durable response to CTLA-4 therapy","volume":"28","author":"Pavlick","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2018.04.046_bib62","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaad.2018.04.046_bib63","unstructured":"US Food and Drug Administration. Adriamycin (doxorubicin HCl). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/062921s022lbl.pdf. Accessed October 24, 2017."},{"key":"10.1016\/j.jaad.2018.04.046_bib64","unstructured":"US Food and Drug Administration. Doxil (doxorubicin HCl liposome injection). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050718s029lbl.pdf. Accessed October 24, 2017."},{"issue":"3","key":"10.1016\/j.jaad.2018.04.046_bib65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-014-2514-9","article-title":"Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx)","volume":"74","author":"Boers-Sonderen","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2018.04.046_bib66","unstructured":"US Food and Drug Administration. Docetaxel injection, solution for intravenous infusion. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/201525s002lbl.pdf. Accessed October 24, 2017."},{"key":"10.1016\/j.jaad.2018.04.046_bib67","unstructured":"US Food and Drug Administration. Taxol (paclitaxel) injection. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020262s049lbl.pdf. Accessed October 24, 2017."},{"key":"10.1016\/j.jaad.2018.04.046_bib68","unstructured":"US Food and Drug Administration. Paraplatin (carboplatin) injection. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020452s005lbl.pdf. Accessed October 24, 2017."},{"key":"10.1016\/j.jaad.2018.04.046_bib69","unstructured":"US Food and Drug Administration. Platinol (cisplatin for injection, USP). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018057s080lbl.pdf. Accessed October 24, 2017."},{"key":"10.1016\/j.jaad.2018.04.046_bib70","unstructured":"US Food and Drug Administration. Xeloda (capecitabine). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020896s037lbl.pdf. Accessed October 24, 2017."},{"issue":"10","key":"10.1016\/j.jaad.2018.04.046_bib71","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/bjc.2012.434","article-title":"Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer","volume":"107","author":"Hofheinz","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.04.046_bib73","unstructured":"US Food and Drug Administration. Erbitux (cetuximab). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/125084lbl.pdf. Accessed October 24, 2017."},{"key":"10.1016\/j.jaad.2018.04.046_bib74","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10147-017-1231-x","article-title":"Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis","volume":"23","author":"Wei","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2014.07.005","article-title":"Correlation of cetuximab-induced skin rash and outcomes of solid tumor\u00a0patients treated with cetuximab: a systematic review and meta-analysis","volume":"93","author":"Abdel-Rahman","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib76","first-page":"33","article-title":"Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker","volume":"7","author":"Bianchini","year":"2008","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"10.1016\/j.jaad.2018.04.046_bib77","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib78","doi-asserted-by":"crossref","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.046_bib79","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","article-title":"The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials","volume":"8","author":"Petrelli","year":"2013","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib80","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials","volume":"78","author":"Petrelli","year":"2012","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3816\/CLC.2009.n.013","article-title":"Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management","volume":"10","author":"Tsimboukis","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2018.04.046_bib82","doi-asserted-by":"crossref","first-page":"849051","DOI":"10.1155\/2009\/849051","article-title":"Clinical significance of skin toxicity due to EGFR-targeted therapies","volume":"2009","author":"Giovannini","year":"2009","journal-title":"J Oncol"},{"key":"10.1016\/j.jaad.2018.04.046_bib83","unstructured":"Saltz L. The presence and intensity of cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. American Society of Clinical Oncology Meeting. 2003:abstract 817."},{"issue":"18","key":"10.1016\/j.jaad.2018.04.046_bib84","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-05-0790","article-title":"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jaad.2018.04.046_bib85","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jaad.2018.04.046_bib86","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2018.04.046_bib87","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib88","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12885-015-1273-2","article-title":"Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions [abstract]","volume":"15","author":"Lee","year":"2015","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.jaad.2018.04.046_bib89","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"280","key":"10.1016\/j.jaad.2018.04.046_bib90","doi-asserted-by":"crossref","first-page":"280sr1","DOI":"10.1126\/scitranslmed.3010274","article-title":"On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation","volume":"7","author":"Lesokhin","year":"2015","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.jaad.2018.04.046_bib91","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"Supplement C","key":"10.1016\/j.jaad.2018.04.046_bib92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"Supplement C","key":"10.1016\/j.jaad.2018.04.046_bib93","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.jaad.2018.04.046_bib94","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage iii-iv melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2018.04.046_bib95","first-page":"1047","article-title":"Development of halo nevi in a lung cancer patient: a novel immune-related cutaneous event from atezolizumab","volume":"16","author":"Birnbaum","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.04.046_bib96","first-page":"2349","article-title":"Effects of alopecia on body image\u00a0and quality of life of Turkish cancer women with or without headscarf","volume":"20","author":"Erol","year":"2012","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.046_bib97","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00002820-199408000-00006","article-title":"Social and cultural dimensions of hair loss in women treated for breast cancer","volume":"17","author":"Freedman","year":"1994","journal-title":"Cancer Nurs"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib98","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1471-6712.1992.tb00128.x","article-title":"Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer","volume":"6","author":"Tierney","year":"1992","journal-title":"Scand J Caring Sci"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.046_bib99","first-page":"903","article-title":"Alopecia and chemotherapy","volume":"80","author":"Welch","year":"1980","journal-title":"AJN Am J Nurs"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/jid.1960.88","article-title":"Changes in scalp hair roots as a measure of toxicity from cancer chemotherapeutic drugs","volume":"35","author":"Crounse","year":"1960","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.046_bib101","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.04.046_bib102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.046_bib103","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2018.04.046_bib104","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.jaad.2018.04.046_bib105","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00262-016-1898-2","article-title":"Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial","volume":"65","author":"Ascierto","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.046_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18050909","article-title":"Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis","volume":"18","author":"Chiramel","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jaad.2018.04.046_bib107","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00280-016-3039-1","article-title":"Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer","volume":"77","author":"Fujii","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.046_bib108","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.lungcan.2013.03.004","article-title":"Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study","volume":"81","author":"Wu","year":"2013","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.046_bib109","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000342425","article-title":"Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma","volume":"84","author":"Koschny","year":"2013","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.046_bib110","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2010.06.051","article-title":"The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies","volume":"65","author":"Balagula","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.04.046_bib111","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.clml.2017.07.005","article-title":"Cutaneous adverse events of targeted therapies for hematolymphoid malignancies","volume":"17","author":"Ransohoff","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218306546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218306546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:46:22Z","timestamp":1759272382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218306546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0190962218306546"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.04.046","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.04.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}